{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:14:46Z","timestamp":1789380886545,"version":"build-2803163510"},"reference-count":37,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.3892\/ijo.2015.2960","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T05:21:47Z","timestamp":1428556907000},"page":"2488-2496","source":"Crossref","is-referenced-by-count":16,"title":["A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells"],"prefix":"10.3892","volume":"46","author":[{"given":"ZI-JIE","family":"LONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LE-XUN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FEI-MENG","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIA-JIE","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YU","family":"LUO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XI-XIANG","family":"TU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DONG-JUN","family":"LIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GUI","family":"LU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QUENTIN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"key20180107184250_b1-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20180107184250_b2-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"39223","DOI":"10.1074\/jbc.M007291200","article-title":"BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase\/AKT pathway","volume":"275","author":"Gesbert","year":"2000","journal-title":"J Biol Chem"},{"key":"key20180107184250_b3-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"key20180107184250_b4-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","article-title":"JAK-STAT signaling activated by Abl oncogenes","volume":"19","author":"Danial","year":"2000","journal-title":"Oncogene"},{"key":"key20180107184250_b5-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+)CD38(\u2212)population to imatinib","volume":"40","author":"Airiau","year":"2012","journal-title":"Exp Hematol"},{"key":"key20180107184250_b6-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2012.19","article-title":"Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL- expressing cells via transcriptional repression of STAT5 and Mcl-1","volume":"26","author":"Soliera","year":"2012","journal-title":"Leukemia"},{"key":"key20180107184250_b7-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"key20180107184250_b8-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20180107184250_b9-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"key20180107184250_b10-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk Res"},{"key":"key20180107184250_b11-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gde.2003.11.006","article-title":"Aurora kinases link chromosome segregation and cell division to cancer susceptibility","volume":"14","author":"Meraldi","year":"2004","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107184250_b12-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A - a guardian of poles","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"key20180107184250_b13-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-09-3953","article-title":"Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells","volume":"70","author":"Cammareri","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107184250_b14-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood-2006-07-037671","article-title":"Targeting aurora kinases as therapy in multiple myeloma","volume":"109","author":"Shi","year":"2007","journal-title":"Blood"},{"key":"key20180107184250_b15-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"key20180107184250_b16-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"key20180107184250_b17-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/1535-7163.MCT-13-1029","article-title":"A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance","volume":"13","author":"Zheng","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20180107184250_b18-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2014.03.027","article-title":"Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors","volume":"78","author":"Luo","year":"2014","journal-title":"Eur J Med Chem"},{"key":"key20180107184250_b19-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett"},{"key":"key20180107184250_b20-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20180107184250_b21-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"key20180107184250_b22-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107184250_b23-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107184250_b24-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1541-7786.MCR-13-0172","article-title":"Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism","volume":"11","author":"Liu","year":"2013","journal-title":"Mol Cancer Res"},{"key":"key20180107184250_b25-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.4161\/cc.7.10.5949","article-title":"ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture","volume":"7","author":"Long","year":"2008","journal-title":"Cell Cycle"},{"key":"key20180107184250_b26-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-9-74","article-title":"Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells","volume":"9","author":"Xu","year":"2011","journal-title":"J Transl Med"},{"key":"key20180107184250_b27-ijo-46-06-2488","first-page":"4403","article-title":"Human acute myeloid leukemia CD34+\/CD38\u2212 progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities","volume":"60","author":"Costello","year":"2000","journal-title":"Cancer Res"},{"key":"key20180107184250_b28-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-9-71","article-title":"Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells","volume":"9","author":"Rao","year":"2011","journal-title":"J Transl Med"},{"key":"key20180107184250_b29-ijo-46-06-2488","first-page":"2706","article-title":"CD34+\/CD38\u2212 acute myelogenous leukemia cells aberrantly express Aurora kinase A","volume":"133","author":"Yang","year":"2013","journal-title":"Int J Cancer"},{"key":"key20180107184250_b30-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/kjh.2012.47.3.178","article-title":"Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells","volume":"47","author":"Kim","year":"2012","journal-title":"Korean J Hematol"},{"key":"key20180107184250_b31-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12308-008-0019-3","article-title":"Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia","volume":"2","author":"Ye","year":"2009","journal-title":"J Hematop"},{"key":"key20180107184250_b32-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1074\/jbc.M311780200","article-title":"BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition","volume":"279","author":"Ouchi","year":"2004","journal-title":"J Biol Chem"},{"key":"key20180107184250_b33-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ccr.2011.12.025","article-title":"Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73","volume":"21","author":"Katayama","year":"2012","journal-title":"Cancer Cell"},{"key":"key20180107184250_b34-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/mp2006714","article-title":"Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202","volume":"9","author":"Cheng","year":"2012","journal-title":"Mol Pharm"},{"key":"key20180107184250_b35-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/j.1582-4934.2010.01218.x","article-title":"The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib","volume":"15","author":"Kelly","year":"2011","journal-title":"J Cell Mol Med"},{"key":"key20180107184250_b36-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"80","DOI":"10.18632\/oncotarget.793","article-title":"Genomic imbalance of HMMR\/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition","volume":"4","author":"Mohan","year":"2013","journal-title":"Oncotarget"},{"key":"key20180107184250_b37-ijo-46-06-2488","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2007-10-116376","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.2960\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T01:12:50Z","timestamp":1566522770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.2960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,4,9]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.3892\/ijo.2015.2960"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.2960","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]}}}